1AMGN.MI
Strong BuyPremium GrowerAI neutralAmgen Inc. · Healthcare · United States · $217.3B cap · $24K/day traded
EUR 423.55 +2.9% · close 30 Oct · scored 3 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on 1AMGN.MI (Nov 2026), freeAs of 3 Nov 2026, MoatMap's StockRank for Amgen Inc. (1AMGN.MI) is 96/100, ranked against 24,000+ stocks in 35 markets (Quality 71, Value 42, Momentum 91, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
Amgen is a large, highly cash-generative biotech with a broad franchise, and its obesity drug candidate MariTide is the key source of upside. Its core products face biosimilar erosion, and it carries significant debt from the Horizon acquisition. The recent news, a sale-leaseback of its Deerfield campus, does not change the picture. The stock is a steady business without a clear asymmetric catalyst.
ABOUT AMGEN INC.
Read
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic...
FINANCIAL SUMMARY (EUR)
Reported in USD
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.0B | 26.1B | 30.9B | 32.5B | 9.2% | 34.0B | 34.8B | 36.0B | 4.8% |
| EPS (EUR) | 11.56 | 11.61 | 7.04 | 12.68 | 3.1% | 13.77 | — | — | — |
| Shares | 534.0M | 535.4M | 537.0M | 538.8M | +0.9% | 540.6M | — | — | — |
| Debt | 36.5B | 58.4B | 57.8B | 46.5B | 8.4% | 51.1B | — | — | — |
| Equity | 3.4B | 5.6B | 5.6B | 7.4B | 29.0% | — | — | — | — |
| Op CF | 9.2B | 7.8B | 10.6B | 8.8B | -1.5% | 11.1B | — | — | — |
| Inv CF | -5.7B | -24.2B | -966.4M | -1.7B | — | — | — | — | — |
| Fin CF | -3.8B | 19.5B | -8.7B | -9.6B | — | — | — | — | — |
Above its 200-day average and 1% below its 52-week high.
Calmer than 75% of stocks we rank over the past year (volatility 29% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1AMGN.MI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1AMGN.MI | Amgen Inc.(you) | $217.3B | 96 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $193.5B | 88 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $125.6B | 96 | Strong Buy |
| NOVO-B.CO | Novo Nordisk A/S | $172.0B | 88 | Strong Buy |
| NVS | Novartis AG | $287.2B | 86 | Strong Buy |
| AZN.ST | AstraZeneca PLC | $264.5B | 84 | Strong Buy |
| PFE | Pfizer Inc. | $171.2B | 84 | Strong Buy |
| ROP.SW | Roche Holding AG | $377.9B | 89 | Strong Buy |
| 1SAN.MI | Sanofi | $95.1B | 93 | Strong Buy |
| GSK | GSK plc | $101.7B | 89 | Strong Buy |
Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 53.7%
Company Deep Dive
Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.